Neoadjuvant chemotherapy: The touchstone of targeted therapy of HER-2 positive breast cancer

柳光宇; 王玉洁

doi:10.3969/j.issn.1007-3969.2013.08.004

您当前的位置：

首页 >

文章列表页 >

Neoadjuvant chemotherapy: The touchstone of targeted therapy of HER-2 positive breast cancer

更新时间：2025-12-31

- Neoadjuvant chemotherapy: The touchstone of targeted therapy of HER-2 positive breast cancer
- China Oncology Vol. 23, Issue 8, Pages: 584-589(2013)
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.08.004
  CLC：
- Published Online：26 February 2014，
  
  Published：2013
- 稿件说明：
移动端阅览
柳光宇,王玉洁. 新辅助疗法：乳腺癌抗HER-2靶向治疗的试金石[J]. 中国癌症杂志, 2013, 23(8): 584-589.

柳光宇, 王玉洁. Neoadjuvant chemotherapy: The touchstone of targeted therapy of HER-2 positive breast cancer[J]. China Oncology, 2013, 23(8): 584-589.
柳光宇,王玉洁. 新辅助疗法：乳腺癌抗HER-2靶向治疗的试金石[J]. 中国癌症杂志, 2013, 23(8): 584-589. DOI： 10.3969/j.issn.1007-3969.2013.08.004.

柳光宇, 王玉洁. Neoadjuvant chemotherapy: The touchstone of targeted therapy of HER-2 positive breast cancer[J]. China Oncology, 2013, 23(8): 584-589. DOI： 10.3969/j.issn.1007-3969.2013.08.004.

摘要

人表皮生长因子受体(human epidermal growth factor receptor 2

HER-2)高表达被视为预后不良的重要预测因素，但随着抗HER-2靶向治疗药物曲妥珠单抗的问世以及化疗联合靶向治疗的应用，其预后逐步得到了改善。新辅助疗法因可作为“体内药敏”试验的特殊优势，成为早期可手术乳腺癌综合治疗的一种新的选择模式。近年来，新一代的抗HER-2靶向药物和治疗方法层出不穷，而在验证其疗效方面，新辅助疗法提供了一个重要的研究平台。现对HER-2过表达乳腺癌新辅助化疗的相关临床试验结果进行分析和解读，并对新近开展的多项针对HER-2过表达乳腺癌的新辅助靶向治疗研究作一综述。

Abstract

The overexpression of human epidermal growth factor receptor 2 (HER-2) is generally considered as an significant predictor of poor prognosis

but the outcome has been rewritten with the appearance and application of the HER-2 targeted monoclonal antibody trastuzumab and chemotherapy plus targeted therapy. For the superiority of acting as "in vivo susceptibility” test

neoadjuvant chemotherapy has become a new comprehensive treatment mode for operable breast cancer. And it has also provided an important approach to investigate the effectiveness of newly appeared targeted therapy. We focused more on reviewing and analyzing the results of clinical trials related to preoperation chemotherapy and the latest studies in HER-2 positive breast cancer in this article.

关键词

Keywords

references

Views

2372

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Research status and progress of third-line treatment for metastatic colorectal cancer

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Research status and prospects of treatment for malignant pleural mesothelioma

Related Author

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

LIU Miao

LI Jinze

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Oncology, The First Affiliated Hospital of Naval Medical University

AI问答

⁰